Please use this identifier to cite or link to this item:
|Title:||Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.|
|Authors:||Louis, William J;McNeil, John J;Anavekar, S N;Conway, Elizabeth L;Workman, B;Howes, L G;Drummer, Olaf H;Jarrott, B|
|Affiliation:||Department of Clinical Pharmacology, Austin Hospital, Heidelberg, Victoria, Australia|
|Citation:||Journal of Cardiovascular Pharmacology; 10 Suppl 12(): S100-3|
|Abstract:||Central and peripheral alpha-adrenoceptors play an important role in cardiovascular regulation, and selective alpha 1-adrenoceptor antagonists and alpha 2-adrenoceptor agonists have an established place in the therapy of hypertension. Prazosin is a selective alpha 1-antagonist that is both effective in lowering blood pressure and well tolerated. However, the more recently developed alpha 1-antagonists doxazosin and terazosin offer the advantage of having longer half-lives, allowing once daily administration. Clonidine is a centrally acting alpha 2-agonist whose clinical use has often been limited by the dose dependent side effects of dry mouth and sedation, and the belief that it should be given three times per day. However, recent studies have shown that it has substantial antihypertensive efficacy with minimal side effects at low doses, and that half-life is long enough to allow twice daily administration. An improved understanding of the pharmacodynamics and pharmacokinetics of drugs acting on alpha-adrenoceptors allows a more rational approach to their clinical application.|
|Internal ID Number:||2455158|
|Subjects:||Adrenergic alpha-Agonists.pharmacokinetics.therapeutic use|
Adrenergic alpha-Antagonists.pharmacokinetics.therapeutic use
Clonidine.adverse effects.pharmacokinetics.therapeutic use
Prazosin.analogs & derivatives.pharmacokinetics.therapeutic use
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.